Background: TP53 is commonly mutated in several cancers and confers treatment resistance
Introduction
TP53 is a common gene to be altered in human cancer; about 50% of solid tumors have altered TP53 gene. Mutations in the TP53 gene are infrequent in AML with normal karyotype (1), however, in AML with a complex karyotype, TP53 is the most frequently altered gene and some studies confirm 70% deletions and/or mutations (1, 2) . The p53 protein plays a key role as a tumor suppressor and functions as a transcription factor controlling genes involved in preventing cancer formation (3) . In hematologic malignancies, TP53 alterations cause resistance to chemotherapy and poor survival (4) . The oncoprotein MDM2 (mouse double minute 2) is a negative regulator of p53. In unstressed cells, the p53 levels are normally very low and regulated by MDM2 mediated ubiquitination of p53. In the absence of stress, p53 and MDM2 are linked to each other through an autoregulatory negative feedback loop that maintains a low concentration level (5) . In stressed cells, p53 is very rapidly activated and accumulates in the nucleus, activating transcription of target genes (5) . MDM2 has been reported to be overexpressed in AML and this may attenuate the p53 signaling pathway and enhance tumor transformation and resistance to apoptosis (6, 7) . A single nucleotide polymorphism (SNP309, rs2279744) located in the promoter region of the MDM2 gene is shown to contribute in regulation of MDM2 levels and influence cellular p53 levels. The SNP309 is a T to G transversion, where the G allele binds with a higher affinity to the SP1 transcription factor than the wild-type T allele, resulting in increased MDM2 mRNA and protein levels and subsequently a decreased p53 level affecting the cellular response to DNA damage (8) . Therefore, the MDM2 SNP309 has potential as a clinical biomarker in AML, with the aim of future treatment individualization and improvement of patient outcomes.
To evaluate the impact of TP53 mutations and MDM2 SNP309 for response to chemotherapy and overall survival we performed TP53 mutation analysis and MDM2 genotyping for the SNP309 on a study group of 189 unselected AML patients. To detect the TP53 status, the single strand conformation analysis (SSCA) was performed. 1µl
Material and Methods

Patients
PCR product was labeled with 32 P-dATP and the same primers as earlier were used in a secondary PCR reaction for 15-20 cycles. Labeled PCR products were diluted 20 times with loading solution (0.1% SDS, 10 mM EDTA, 50% formamide, xylene-cyanol and bromo-phenol blue). The DNA samples were heat denatured 95° for 3 min and rapidly cooled and the products were subsequently separated on a 6% non-denaturing polyacrylamide gel containing 10%
glycerol and the fragments were separated at 6 W for 16 hours at room temperature followed by autoradiography. Samples with mobility shift were sequenced to determine the exact nucleotide sequence and compared to the corresponding TP53 reference sequence (NM_000546.4).
MDM2 SNP309 genotyping
PCR amplification of the MDM2 gene region covering the promoter SNP309 (rs2279744) was performed using the HotStarTaq master mixture (VWR International, Stockholm, Sweden) with primers and MgCl2 at final concentrations of 0.4 mM and 1.5 mM, respectively, in a total volume of 10 µL. The PCR primers were forward CGGGAGTTCAGGGTAAAGGT and reverse biotin-TCGGAACGTGTCTGAACTTG. The SNP was analyzed using Pyrosequencing on a PyroMark 96MD instrument (Qiagen, Sweden) according to the manufacturers´ instructions.
Briefly, the biotinylated DNA strand was isolated using the Pyrosequencing Vacuum Prep
Work Station (Qiagen, Sweden) and the sequencing primer CAGGGTAAAGGTCACG was annealed to the template at 80°C for 2 minutes. After cooling to room temperature, the sample plate was transferred to the Pyrosequencing instrument and sequencing was performed with the nucleotide dispensing order TGGCGGCTGCGGCGCTGTC. The genotype frequencies found in our patient material was compared to a material of 214 healthy controls. In this study, we also analyzed the prognostic impact of a regulatory polymorphism, MDM2 SNP309 , in the 189 de novo AML patients, as an indication of an impaired p53 function.
Statistical analysis
Overexpression of MDM2, the negative regulator of p53, is an alternative way to attenuate a cellular p53 response in the absence of TP53 mutation/deletion. We found a negative influence on OS in TP53 wild type AML patients with an intermediate/high risk karyotype and at least one G-allele of MDM2 SNP309 . This effect was neither observed in OS analysis of the entire group, nor in the CN-AML patients, suggesting that the SNP G-allele carriers may suppress function of wild-type p53 in cytogenetically altered tumors. Ellis et al. performed a study in therapy-related AML (t-AML) where the patients had previously been treated with chemotherapy and/or radiotherapy for other types of tumors, and no significant association between MDM2 SNP309 and t-AML was found (12) . A Chinese group reported a 3.52 increased AML risk associated with the SNP G/G genotype compared to the SNP T/T genotype, but reported no association with the G/G genotype and earlier age of onset (13) . The authors reported no data about treatment and survival. In contrast to the study by Xiong et al., we found no generally increased AML risk associated with MDM2 SNP309 genotype. However, there were a higher proportion of G/G cases in our cytogenetically altered AML cases, indicating that this MDM2 variant may influence the normal repair systems via increased attenuation of normal p53 responses, thereby driving the disease towards a more high risk cytogenetic profile.
Allo-SCT in first complete remission improves the prognosis in AML patients with intermediate or high risk (9, 14) . However, some patients, including those with monosomal karyotype, and, as seen in our study, patients with TP53 mutation, are unlikely to reach CR with standard treatment. These patients may be considered for clinical trials with emerging novel therapies targeting the p53 signaling pathway. Drug candidates with the potential of restoring p53 activity in hematological malignances include small molecules such as the nutlins, RITA ("Reactivation of p53 and Induction of Tumour cell Apoptosis") and PRIMA-1 ("p53
Reactivation and Induction of Massive Apoptosis") (15) (16) (17) (18) . The nutlins act by inhibiting the p53 inhibitor MDM2, and are mainly an option in TP53 wild-type patients with increased MDM2 expression and activity. Based on our results, genotyping patients for the SNP309, which increase MDM2 expression and p53 inhibitory activity, may be a feasible option for selecting the patients most likely to benefit from future treatment regimens with nutlins.
Similarly, RITA induces p53 accumulation in AML cells, presumably by inhibiting p53-MDM2 interaction, with an effect predominantly in TP53 wild-type cells (19) . In contrast, PRIMA-1 has been shown to induce cytotoxic effects in AML cells by restoring the transcriptional activity of mutated p53 (16, 17, 19) . Safety and pharmacokinetic profile appear favorable, and cross resistance with conventional chemotherapy drugs or P-glycoprotein mediated resistance appear unlikely (16, 20) . Standard cytogenetic analysis is able to detect patients with loss of chromosome 17 material, but does not detect TP53 mutations. Also, a small number of cytogenetically normal AML patients do harbor TP53 mutations and have a poor prognosis similar to patients with high risk cytogenetics. Thus, the analysis of TP53 mutations would provide important prognostic information in AML.
Conclusions
We have found TP53 to be mutated in a high frequency of AML cases with aberrant, high risk cytogenetics, with a low rate of CR and markedly reduced OS. Also, aberrant karyotype patients with wild-type TP53 but the variant allele of the MDM2 SNP309 appears to have a reduced OS.
Clinical trials as well as preclinical in vivo studies with nutlins, RITA and PRIMA-1 in hematological malignancies are in progress, and combination therapies with drugs targeting p53 or MDM2-p53 interactions and conventional drugs are likely to improve outcomes (20, 21) . The exact dosing and most effective drug combinations remain to be identified, but our study implies that analysis of polymorphisms affecting endogenous p53-inhibitors, such as the MDM2 SNP309 , as well as the analysis of TP53 mutational status should serve as important tools for prognostication and risk stratification, as well as selection of patients most likely to benefit from novel experimental therapies with drugs targeting the p53 signaling pathway. 
